Karyopharm to Participate at Upcoming Investor Conferences

In this article:

NEWTON, Mass., Sept. 5, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in September:

(PRNewsfoto/Karyopharm Therapeutics Inc.)
(PRNewsfoto/Karyopharm Therapeutics Inc.)

H.C. Wainwright 25th Annual Global Investment Conference
Format: Podium presentation
Date: Monday, September 11, 2023
Time: 12:30 p.m. ET

Morgan Stanley 21st Annual Global Healthcare Conference
Format: Fireside chat
Date: Tuesday, September 12, 2023
Time: 5:30 p.m. ET

Baird 2023 Global Healthcare Conference
Format: Fireside chat
Date: Wednesday, September 13, 2023
Time: 2:00 p.m. ET

A live webcast of the presentation and fireside chats, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay for 90 days following each presentation.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been an industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic neoplasms and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on Twitter at @Karyopharm and LinkedIn.

CisionCision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-upcoming-investor-conferences-301918139.html

SOURCE Karyopharm Therapeutics Inc.

Advertisement